Skip Navigation



Mathematical Medicine and Biology Advance Access published online on July 25, 2007
Mathematical Medicine and Biology, doi:10.1093/imammb/dqm003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/3/287    most recent
dqm003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rodríguez-Pérez, D
Right arrow Articles by Antoranz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodríguez-Pérez, D
Right arrow Articles by Antoranz, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The author 2007. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications. All rights reserved.

Assessment of cancer immunotherapy outcome in terms of the immune response time features

D Rodríguez-Pérez{dagger}, Oscar Sotolongo-Grau and Ramón Espinosa Riquelme

Departamento de Física Matemática y de Fluidos, UNED, PO Box 60141, 28080 Madrid, Spain

Oscar Sotolongo-Costa

Department of Theoretical Physics, Henry Poincaré Group of Complex Systems, Havana University, Havana, Cuba

J. Antonio Santos Miranda

Servicio de Oncología Radioterápica, H.G.U. Gregorio Marañón, Madrid, Spain

JC Antoranz

Departamento de Física Matemática y Fluidos, UNED, 28080 Madrid, Spain and Department of Theoretical Physics, Henry Poincaré Group of Complex Systems, Havana University, Havana, Cuba

{dagger} Email: daniel{at}dfmf.uned.es

Received on 28 July 2006. Revised on 26 March 2007.
  Abstract

A cytokine-based periodic immunotherapy treatment is included in a model of tumour growth with a delay. The effects of dose schedule are studied in the case of a weak immune system and a growing tumour. We find the existence of ‘metastable’ states (that may last for tens of years) induced by the treatment and also potentially adverse effects of the dosage frequency on the stabilization of the tumour. These two effects depend on the delay between the tumour growth and the immune system response, the cytokine dose burden, and other parameters considered in the model.

Keywords: tumour growth; delay differential equations; immunotherapy; immunodepression


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.